Establishment of a platform for measuring mitochondrial oxygen consumption rate for cardiac mitochondrial toxicity
Authors:
- 10 May 2022
- journal article
- research article
- Published by Springer Nature in Toxicological Research
- Vol. 38 (4) , 511-522
Abstract
The heart has an abundance of mitochondria since cardiac muscles require copious amounts of energy for providing continuous blood through the circulatory system, thereby implying that myocardial function is largely reliant on mitochondrial energy. Thus, cardiomyocytes are susceptible to mitochondrial dysfunction and are likely targets of mitochondrial toxic drugs. Various methods have been developed to evaluate mitochondrial toxicity by evaluating toxicological mechanisms, but an optimized and standardized assay for cardiomyocytes remains unmet. We have therefore attempted to standardize the evaluation system for determining cardiac mitochondrial toxicity, using AC16 human and H9C2 rat cardiomyocytes. Three clinically administered drugs (acetaminophen, amiodarone, and valproic acid) and two anticancer drugs (doxorubicin and tamoxifen) which are reported to have mitochondrial effects, were applied in this study. The oxygen consumption rate (OCR), which directly reflects mitochondrial function, and changes in mRNA levels of mitochondrial respiratory complex I to complex V, were analyzed. Our results reveal that exposure to all five drugs results in a concentration-dependent decrease in the basal and maximal levels of OCR in AC16 cells and H9C2 cells. In particular, marked reduction in the OCR was observed after treatment with doxorubicin. The reduction in OCR after exposure to mitochondrial toxic drugs was found to be associated with reduced mRNA expression in the mitochondrial respiratory complexes, suggesting that the cardiac mitochondrial toxicity of drugs is majorly due to dysfunction of mitochondrial respiration. Based on the results of this study, we established and standardized a protocol to measure OCR in cardiomyocytes. We expect that this standardized evaluation system for mitochondrial toxicity can be applied as basic data for establishing a screening platform to evaluate cardiac mitochondrial toxicity of drugs, during the developmental stage of new drug discovery.Keywords
Funding Information
- National Institute of Food and Drug Safety Evaluation (20183MFDS525)
This publication has 53 references indexed in Scilit:
- Direct, Differential Effects of Tamoxifen, 4-Hydroxytamoxifen, and Raloxifene on Cardiac Myocyte Contractility and Calcium HandlingPLOS ONE, 2013
- Mitochondrial dynamics in the adult cardiomyocytes: which roles for a highly specialized cell?Frontiers in Physiology, 2013
- Cytotoxicity effects of amiodarone on cultured cellsExperimental and Toxicologic Pathology, 2012
- Optical probes and techniques for O2 measurement in live cells and tissueCellular and Molecular Life Sciences, 2012
- High Throughput Microplate Respiratory Measurements Using Minimal Quantities Of Isolated MitochondriaPLOS ONE, 2011
- Assessing mitochondrial dysfunction in cellsBiochemical Journal, 2011
- Mitochondrial proton and electron leaksEssays in Biochemistry, 2010
- Doxorubicin CardiomyopathyCardiology, 2009
- Cytotoxicity and mitochondrial dysfunction of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in isolated rat hepatocytesToxicology Letters, 2009
- Anticonvulsant valproic acid inhibits cardiomyocyte differentiation of embryonic stem cells by increasing intracellular levels of reactive oxygen speciesBirth Defects Research Part A: Clinical and Molecular Teratology, 2003